What is survodutide?

Survodutide is an investigational once weekly drug that activates both the GLP-1 and glucagon receptors, studied for obesity and for MASH, a form of metabolic liver disease involving fat and inflammation in the liver beyond simple fatty buildup. This site's review found 3 human citations for it, covering 387 participants; it is not FDA approved anywhere.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.